Donor T Cell Depletion in Preventing Graft Versus Host Disease in Patients with Blood Cancer Undergoing a Donor Stem Cell Transplant

Inclusion Criteria

• Diagnoses and stage at time of transplant admission: * Acute leukemia (acute myeloid leukemia [AML] or acute lymphoblastic leukemia [ALL] or mixed phenotype acute leukemia [MPAL]) in first or subsequent remission * Myelodysplastic syndromes (MDS) with < 10% marrow blasts * Myeloproliferative neoplasm (MPN) with < 10% marrow blasts * Chronic myelomonocytic leukemia (CMML) with less than 10% marrow blast * Chronic myelogenous leukemia (CML) accelerated phase or second or subsequent chronic phase * Non-Hodgkin’s lymphoma in partial remission (PR) or second complete remission (CR2) or beyond * Hodgkin lymphoma in PR or CR2 or beyond.
• Patient has a related or unrelated donor who is 8 or 9 out of 10 match at human leukocyte antigen (HLA) A, B, C, DRB1 and DQB1, based on allele level typing.
• Patient Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky >= 60%).
• Patient deemed to be appropriate candidate for myeloablative conditioning transplantation.
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

• Patient with active human immunodeficiency virus (HIV) infection.
• Chronic active hepatitis B infection (hepatitis B [HepB] surface antigen [Ag]+ or detectable Hep B viral load).
• Prior allogeneic hematopoietic stem cell transplantation.
• Impaired cardiac function- ejection fraction < 40%.
• Impaired pulmonary function- pretransplant forced expiratory volume in one second (FEV1), diffusion capacity of the lung for carbon monoxide (DLCO) < 50%.
• Impaired renal function, based on serum creatinine > 2.0 mg/dl.
• Impaired liver function unrelated to primary disease, based on * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x upper limit of normal (ULN), or * Total bilirubin > 2.0 mg/dl (with exception for known or suspected Gilbert’s disease).
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Women who are pregnant or breast feeding. Women of child bearing potential must have a negative serum pregnancy test at study entry.
• Participants who are receiving any other investigational agents are eligible but such agent must be discontinued before admission for hematopoietic stem cell transplantation (HSCT), and if resumption of investigation agent is planned after HSCT, this must be approved by the study principal investigator (PI).
• Participants with known active central nervous system (CNS) disease. CNS disease that has been treated is eligible.